Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Stemline Therapeutics Inc. STML

Healthcare Biotechnology
Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Its pipeline product candidates include felezonexor (SL-801, an XPO1 inhibitor), SL-1001 (a RET kinase inhibitor), SL-901 (a kinase inhibitor) and SL-701 (an... see more

Recent & Breaking News (NDAQ:STML)

Stemline Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference

Globe Newswire May 31, 2013

Stemline Therapeutics Announces Presentations at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting

Globe Newswire May 30, 2013

Stemline Therapeutics Announces Exercise of Option to Purchase Additional Shares

Globe Newswire May 23, 2013

Stemline Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Globe Newswire May 22, 2013

Stemline Therapeutics Prices $60 Million Public Offering of Common Stock

Globe Newswire May 16, 2013

Stemline Therapeutics to Present at the 12th Annual Needham Healthcare Conference on May 1, 2013

Globe Newswire April 25, 2013

Stemline Therapeutics, Inc. Announces Presentation of SL-401 Preclinical Efficacy in Multiple Myeloma at the 14th International Myeloma Workshop in Kyoto, Japan

Globe Newswire April 8, 2013

Stemline Therapeutics Reports Year-End 2012 Financial Results

Globe Newswire April 1, 2013

Stemline Therapeutics to Present at the 25th Annual Roth Conference on March 20, 2013

Troy Schwensen March 12, 2013

Stemline Therapeutics to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013

Troy Schwensen February 27, 2013

Stemline Therapeutics to Present at Leerink Swann and Company Global Healthcare Conference

Troy Schwensen February 12, 2013

NASDAQ Welcomes Stemline Therapeutics, Inc. to The NASDAQ Stock Market

Troy Schwensen February 8, 2013

Stemline Therapeutics, Inc. [STML] to Ring The NASDAQ Stock Market Opening Bell in Celebration of Initial Public Offering

Troy Schwensen February 8, 2013

Stemline Therapeutics, Inc. to Present at BIO CEO & Investor Conference on February 11th

Troy Schwensen February 7, 2013

Stemline Therapeutics, Inc. Announces Closing of Initial Public Offering

Troy Schwensen January 31, 2013

Stemline Therapeutics, Inc. Announces Exercise of Over-Allotment Option

Troy Schwensen January 29, 2013

Stemline Therapeutics, Inc. Announces Pricing of Initial Public Offering of 3,317,644 Shares of Common Stock

Troy Schwensen January 28, 2013